![](https://agenda.euractiv.com/sites/default/files/styles/ea_company_list/public/eatex.png?itok=AkV2kNbs)
EURATEX GENERAL ASSEMBLY - Public Part
Date
Address
Section
Event Location
Event Description
EURATEX GENERAL ASSEMBLY - Public Part - 8th June 2017 - 11 a.m. - 1 p.m - The Hotel - Brussels
Circular Economy into European manufacturing, the case of textile and apparel industry
Objective
To discuss both success stories and the needs of European textiles and apparel companies which profit from the circular economy. To showcase what the sector is doing and to explain what European support is needed to multiply the circularity business model across the European sector, particularly SMEs. To present the EURATEX circular economy paper.
Format
Panel discussion with the EU institutions and four companies followed by Q&A.
Confirmed Keynote speaker: Mr. Grzegorz Radziejewski, member of the cabinet of the Commission Vice President Katainen
Related Events
Securing Europe‘s Raw Material Supply in the Context of Resource Efficiency and EU Industry Policy
There is no energy- and resource efficiency, no climate protection, no future technologies for our modern
world without the use of non-ferrous metals.
Monday 5 November 2012 (day 1)
15:00-16:30: European Parliament Briefing (optional): Enterprise Forum members will have the opportunity to attend a briefing on how the European Parliament works. Paul-Henri Spaak Building, Rue Wiertz, B-1047 Brussels
SMEs are the backbone of the European economy. Of the approximately 20 million SMEs in Europe, one third is active in the field of commerce.
COST will be a partner of the fourth European Innovation Summit to be held at the European Parliament in Brussels under the motto 'Building bridges – Creating Synergies'.
Knowledge4Innovation will be organising the 4th European Innovation Summit from 9 to 10 October 2012 in the European Parliament in Brussels.
An existing literature agrees that drug innovation has a significant average effect on extending longevity and improving quality of life. Recognizing the life-saving benefits from the development of new drugs, one of the key decisions faced by the authorities is how to bolster pharmaceutical innovation, and how to bear in mind the potential effects on drug innovation of policies that affect market size, such as policies towards intellectual property rights, procurement mechanisms and competition policy.
Pages
Events of the week
Jobs
EURACTIV News
- White hat hacker shines spotlight on vulnerability of solar panels installed in Europe
- German, Austrian finance ministers prepare for EU dispute over public vs private investment
- Nord Stream attack: Germany issues arrest warrant for Ukrainian suspect
- Edmundo González will be sworn in as Venezuela president in 2025, says leading opposition politician
- US aligns with EU on Google antitrust case, hinting at enforcement measures